Skip to content
AnalystLens

CVS HEALTH Corp 8-K Report, Regulation FD Disclosure (Dec 9, 2025)

Reports
Regulation FD·Exhibits & Filings
Filing Date
Filed December 9, 2025
Period End
December 9, 2025
Security
CVS
In the record · 2016–202610-K1110-Q328-K181

CVS filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 181 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Nov ’18Nov ’18
  2. Leadership change8-K · Sep ’22Sep ’22
  3. Leadership change8-K · Nov ’24Nov ’24

01—Abstract

Summary

Summary of the 8-K filed December 9, 2025. Cited figures are marked; the original filing is the authoritative source.

CVS Health used its December 9, 2025 Investor Day to reset its outlook and set multi-year targets.

It raised 2025 guidance modestly across the board: total revenues of at least $400.0 billiona (from at least $397.3 billion), adjusted EPS of $6.60 to $6.70 (from $6.55 to $6.65), and adjusted operating income of $14.22 to $14.39 billion (from $14.14 to $14.31 billion). GAAP diluted EPS remains negative at $(0.32) to $(0.22), though that range also improved from prior guidance. Cash flow from operations guidance of $7.5 to $8.0 billion was confirmed.

The increases are small, roughly 0.5% to 1% at the midpoint, so the update is more a confirmation of momentum than a major beat. The more important news for investors is 2026 guidance and the multi-year target. CVS initiated 2026 adjusted EPS guidance of $7.00 to $7.20b, implying roughly 6% to 9% growth over the 2025 range.

It also guided to adjusted operating income of $15.07 to $15.41 billionc, GAAP diluted EPS of $5.94 to $6.14, and cash flow from operations of at least $10.0 billion, a sizable step up from 2025. Management committed to a mid-teens adjusted EPS CAGR through 2028, driven by a return to target margins at Aetna, share wins at CVS Caremark, and a path toward breakeven in Health Care Delivery. The company also announced an AI-native, open consumer engagement platform, though the filing gives few financial details on it.

The 2025 GAAP results carry large one-time charges, including a $5.725 billiond goodwill impairment in Health Care Delivery, $1.22 billion in legacy litigation charges, and a $288 million loss on Accountable Care assets. Management also disclosed a $387 million Omnicare-related False Claims Act charge in Q1 and a $542 million penalty charge in Q2. Together, these explain the negative GAAP EPS against positive adjusted EPS.

Investors should weigh the adjusted figures alongside these recurring-looking legacy litigation and impairment items. Also note that Omnicare deconsolidated after its Chapter 11 filing, which produced a $0.38 per share gain that flows through 2025 adjusted results.

02—Key points

Key Highlights

  1. 2025 guidance raised modestly: adjusted EPS to $6.60–$6.70 (from $6.55–$6.65), total revenues to at least $400.0B (from at least $397.3B), and adjusted operating income to $14.22–$14.39B; cash flow from operations of $7.5–$8.0B was confirmed.
  2. 2026 initial guidance: adjusted EPS of $7.00–$7.20, adjusted operating income of $15.07–$15.41B, GAAP diluted EPS of $5.94–$6.14, and cash flow from operations of at least $10.0B.
  3. Multi-year target: mid-teens adjusted EPS CAGR through 2028, anchored by Aetna margin recovery, CVS Caremark client wins, and Health Care Delivery reaching breakeven.
  4. GAAP 2025 EPS remains negative at $(0.32)–$(0.22), reflecting a $5.725B goodwill impairment in Health Care Delivery and $1.22B in legacy litigation charges.
  5. Legacy litigation charges include Omnicare False Claims Act damages ($387M in Q1 and $542M in Q2) and a $291M PBM remuneration reporting judgment in Q2 2025.
  6. Omnicare's Chapter 11 filing in September 2025 led to deconsolidation and a $0.38 per share non-GAAP gain in 2025 adjusted results.
  7. Announced an AI-native, open consumer engagement platform ("Engagement as a Service") to integrate experiences across CVS entities and industry partners; no financial targets were disclosed.

03—Questions

Frequently Asked Questions

  1. How much did CVS raise its 2025 guidance, and does the change matter?

    The increases were modest. Adjusted EPS rose by $0.05 at both ends of the range to $6.60–$6.70, and adjusted operating income rose about $80 million. The bigger signal is that management confirmed momentum and reaffirmed cash flow guidance of $7.5–$8.0B, rather than delivering a major beat.

  2. What does the 2026 guidance imply for earnings growth?

    The midpoint of 2026 adjusted EPS guidance ($7.10) is about 7% above the 2025 midpoint ($6.65). Cash flow from operations is guided to at least $10.0B, well above the 2025 range, which suggests stronger underlying cash generation if the plan holds.

  3. Why are GAAP EPS and adjusted EPS so different in 2025?

    Large non-GAAP items drive the gap. These include a $5.725B goodwill impairment (about $4.50 per share), $1.22B in legacy litigation charges (about $0.96 per share), $288M in losses on Accountable Care assets, and amortization of intangibles (about $1.57 per share). The Omnicare deconsolidation gain partly offsets these, at about $0.38 per share.

  4. What is the mid-teens EPS CAGR target based on, and what are the risks?

    The target relies on restoring Aetna to target margins, winning and retaining business at CVS Caremark, sustaining CVS Pharmacy earnings, and reaching Health Care Delivery breakeven. The filing gives no bridge or detailed assumptions, so investors should treat it as an aspiration that depends on execution, and note that the 2025 results included several large one-time charges.

  5. Are the legacy litigation charges and the Omnicare situation likely to recur?

    The filing describes the charges as relating to past business practices, which are largely pre-2018 for Omnicare and 2010–2016 for the PBM matter. However, the filing does not say whether further liabilities remain. The Omnicare Chapter 11 process could also create additional uncertainty, so investors should review future filings for updates on contingent exposures.

04—Continue

← View all 8-K filings